Clinical Trials Logo

Laryngomalacia clinical trials

View clinical trials related to Laryngomalacia.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04614974 Active, not recruiting - Clinical trials for Gastro Esophageal Reflux

Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia

Start date: November 18, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Laryngomalacia (LM) is the most common cause of stridor in infants. Symptoms of gastroesophageal reflux (GER) are often seen in the setting of LM; therefore, acid suppression therapy (AST) has been empirically used in the management of this disorder. The investigators recently performed a retrospective chart review assessing improvement of airway and dysphagia symptoms, weight gain, and need for surgery with AST. It was found that there was a similar improvement between LM severity groups and most patients received AST (96.6%). It is unclear if these improvements are due to AST or natural resolution of the disease. With heightened concerns of side effects related to AST in infants, particularly among those born prematurely, judicious use of these medications is needed. The investigators are now performing a prospective study looking at the outcome differences in patients with laryngomalacia who are evaluated by speech language therapy (SLP) alone versus those with SLP evaluation and acid suppression therapy (famotidine).